Item 3.02. Unregistered Sales of Equity Securities.
On or about November 24, 2023, Ainos, Inc., a Texas corporation (the "Company"), will issue 3,000,000 shares of the Company's common stock, par value $0.01 ("Common Stock"), as Special Stock Awards to certain officers, directors, and management of the Company as follows:
Name
Number of shares
Position in Company
Chun-Hsien Tsai
250,000
Chairman of the Board
Chun-Jung Tsai
250,000
Director
Wen-Han Chang
250,000
Director, Chairperson Compensation Committee, Member Audit Committee
Yao-Chung Chiang
250,000
Director, Member Audit Committee
Pao-Sheng Wei
250,000
Director, Chairperson Audit Committee, Member Compensation Committee
Ting-Chuan Lee
250,000
Director
Chung-Yi Tsai
250,000
Director
Chun-Hsien Tsai
630,000
President and CEO
Chih-Heng Lu
300,000
Director of Corporate Development
Lawrence K Lin
10,000
Executive Vice President of Operations
Jun Lee
10,000
Chief Legal Counsel
Meng Lin Sung
300,000
CFO
Total
3,000,000
The shares of Common Stock described above are not registered under the Securities Act of 1933, as amended (the "Securities Act"), in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act and/or Regulation D promulgated thereunder.
Ainos Inc. published this content on 24 November 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 24 November 2023 13:08:04 UTC.
Ainos, Inc. is a diversified healthcare company, which is focused on the development of point-of-care testing (POCT), low-dose VELDONA interferon therapeutics and synthetic Ribonucleic Acid (RNA)-driven preventative medicine. The Company's products include VELDONA clinical-stage human therapeutics, VELDONA Pet cytoprotein health supplements, and telehealth-friendly POCTs powered by its AI Nose technology platform. VELDONA Pet is formulated to address a variety of health issues in dogs and cats, including skin, gum, emotion, discomfort caused by allergies, eye, and weight-related issues. Its pipeline of products, which are under development, includes VELDONA human drugs, VOC POCT-Ainos Flora, VOC platform-NISD co-development, VOC POCT-Ainos Pen, VOC POCT-CHS430 and Synthetic RNA. VELDONA human drugs are the high-priority programs include oral warts for human immunodeficiency virus seropositive patients, common cold, influenza, Sjogrens syndrome and treatment for mild COVID-19 symptoms.